Microbix And Hunan Biopharmaceutical Group To Set Up Influenza Vaccine Production Base
This article was originally published in PharmAsia News
Executive SummaryCanada-based Microbix and Hunan Biopharmaceutical Group will jointly set up an influenza vaccine base in the Changsha National Biomedical Industrial Base. This represents the largest collaboration between China and Canada since the establishment of diplomatic relations. Both parties have reached an agreement to begin phase I construction in the first half of next year. With an investment of RMB 1.4 billion ($205 million), the project will comply with U.S. and EU standards. After completion, the facility will be the world's third largest influenza vaccine production base. (Click here for more - Chinese language)
You may also be interested in...
HBW Executive Decisions: HELP Endorses Hahn, Industry Award For AHPA's McGuffin, CHPA, Herbalife Hires
CHPA adds Allgaier to head development, relations; Vetere joins Herbalife as VP, CIO; Hahn's FDA commissioner nomination clears HELP committee; and AHPA's McGuffin recognized as 2019 Industry Leader.
Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.
Tech Companies Grappling With A Brave New World Of Regulations While Developing Digital-Health Products
Software firms interested in the digital-health arena are engaging US FDA more and bolstering their regulatory credentials to navigate an unfamiliar regulatory landscape, industry experts tell Medtech Insight.